Introduction
============

The heart is the first functional organ that is developed in the process of embryonic development. It is very important for development that the heart is healthy. Numerous studies have revealed the accurate regulation of key molecular pathways during embryonic development, particularly in the cardiovascular system. Haploinsufficiency of essential genes often leads to cardiac malformations [@B1], which are the most common major congenital defects, with a prevalence of approximately eight in every 1,000 newborn infants [@B2].

The human transcriptome is composed of not only a large set of protein-coding messenger RNAs (mRNA), but also many non-protein coding transcripts that have structural, regulatory or unknown functions. Over the last decade, much attention focused on the microRNAs (miRNAs), a class of small non-coding RNAs that are involved in various biological and pathological processes [@B3], [@B4]. More recently, long non-coding RNAs (lncRNAs), generally defined as non-coding RNAs of more than 200nt in length without known protein-coding function [@B5], have risen to prominence, with central roles in a diverse range of functions in cell biology [@B6],[@B7]. In contrast to miRNAs, lncRNAs have not been fully investigated. A handful studies have indicated that dysregulation of lncRNAs result in aberrant gene expression associated with cancers [@B8]-[@B10]. Although an increasing number of lncRNAs have been characterized, the role of lncRNAs in the differential of cardiomyocytes has not been investigated.

The P19 mouse embryonal carcinoma cell line is multipotent and can differentiate into cardiac myocytes with embryoid body formation in the presence of dimethylsulfoxide (DMSO) [@B11]. Thus, P19 cells have been used to study cardiac-specific transcription factors and upstream signaling pathways in cardiac differentiation [@B12]-[@B14]. Therefore, P19 cells are a suitable model for studying cardiac differentiation at the molecular and functional levels [@B15].

In this study, we initially identified differentially expressed lncRNAs during the differentiation of P19 cells using an lncRNA microarray. We subsequently validated the microarray results by real-time quantitative reverse transcription PCR (real-time qRT-PCR) for specific differentially expressed lncRNAs.

Results and Discussion
======================

P19 cells differentiation
-------------------------

P19 cells differentiate into cardiac myocytes in the presence of DMSO. The efficiency of differentiation depends on the prior formation of non-adhering aggregates [@B17]. We observed and photographed the morphological changes in P19 cells using an inverted microscope to investigate the process of P19 cell differentiation. We discovered that P19 cells aggregated during the first 4 days and there were beating cell colonies on day 10 (Figure [1](#F1){ref-type="fig"}). The myocyte differentiation marker cTnT was detected on day 0 and day10, respectively, to validate that the cells had differentiated into cardiac myocytes. As shown in Figure [2](#F2){ref-type="fig"} and Figure [3](#F3){ref-type="fig"}, mRNA expression and protein expression of cTnT were much higher on day 10 compared to day 0. Thus, the beating cell colonies generated on day 10 of P19 cell differentiation, and the high expression of cTnT, demonstrated that the cells had differentiated into cardiac myocytes.

lncRNA microarray
-----------------

LncRNA microarrays are powerful tools for studying the biological function of lncRNAs. We conducted lncRNA microarray analysis on P19 cells at day 0 and day 10 of DMSO exposure. According to the microarray data, we selected lncRNAs that were upregulated by more than five-fold and downregulated by more than three-fold. In addition, poorly conserved lncRNAs were excluded. The conservation of lncRNAs was determined using the online Basic Local Alignment Search Tool (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>). Ultimately, 40 differentially expressed lncRNAs that were highly conserved in cardiac myocytes (day 10) compared to normal P19 cells (day 0) were identified (Table [1](#T1){ref-type="table"}). Among them, 28 were upregulated and 12 were downregulated. We randomly chose five upregulated lncRNAs (ENSMUST00000159006, uc009byc.1, AK089560, ENSMUST00000101005, ENSMUST00000124503) and three downregulated lncRNAs (uc007keu.1, AK028257, BC030682) for qRT-PCR validation (Table [2](#T2){ref-type="table"}).

Validation of differentially expressed lncRNAs
----------------------------------------------

We performed real-time qRT-PCR expression analysis on P19 cells at day 0 and day 10 to confirm the microarray results. Using GAPDH as a normalization control, the statistics demonstrated that four out of the five upregulated lncRNAs (P=0.038, 0.000016, 0,022 and 0.017 for ENSMUST00000159006, uc009byc.1, AK089560, ENSMUST00000124503, respectively) and two of the three downregulated lncRNAs (P=0.00012 and 0.001 for AK028257 and uc007keu.1, respectively) showed significantly different expressions (Figure [4](#F4){ref-type="fig"}). In addition, we validated the eight differentiated expressed lncRNAs at different time points during the differentiation. D0, d4, d6, d8, d10 were chosen as the time points. As shown in the figure [5](#F5){ref-type="fig"}, the expressed trends during the differentiation are consistent with the comparison between d0 and d10. The major difference might be the beginning time of the change was different.

Discussion
==========

Congenital heart defects (CHD) are the most common major congenital malformation, accounting for approximately 40% of perinatal deaths and more than one fifth of deaths in the first month of life [@B18]. Although many studies have focused on heart development in recent decades, details of the mechanism remain unclear [@B19], [@B20]. P19 cells are isolated from an experimental embryo-derived mouse teratocarcinoma and can differentiate into cardiac myocytes with embryoid body formation in the presence of DMSO [@B21]. Thus, we simulated heart development in vitro by differentiating P19 cells into cardiomyocytes.

This study focused on determining the lncRNAs expression profile during cardiomyocyte differentiation and explaining the differences between cardiomyocytes and undifferentiated P19 cells. We identified 40 differentially expressed lncRNAs (28 upregulated and 12 downregulated). Real-time qRT-PCR validated four of five upregulated and two of three downregulated lncRNAs.

Some researchers have demonstrated that the expression of many lncRNAs is different during development and that their functions range from the control of pluripotency to lineage specification [@B22], [@B23]. In theory, lncRNAs have intrinsic cis-regulatory capacity, which has been confirmed and whose mechanism has been described. Increasing numbers of reports show that lncRNAs can play a role in both cis and trans [@B24], [@B25], and more direct experimental studies are required to determine the precise proportion of cis regulators. Regulating the expression of some lncRNAs may influence the expression of their neighboring protein-coding genes, including several master regulators of cellular differentiation [@B26]-[@B28]. It is in the early stage that the role of lncRNAs in heart development has attracted much attention from researchers. Indeed, two lncRNAs, *Fendrr*and Braveheart (Bvht), were recently uncovered to be involved in the development of the lateral mesoderm in the heart and the differentiation of cardiac myocytes, respectively [@B29], [@B30]. Deficiency of *Fendrr*, particularly in the nascent lateral plate mesoderm, can result in a thin ventricular wall of the heart. *Fendrr*regulates the expression of certain core transcription factors in heart development by modulating the epigenetic profile of cells to generate cardiac hypoplasia [@B29]. In a similar way to *Fendrr*, *Bvht*interacts with SUZ12, a component of PRC2, to alter cardiomyocytes differentiation and retain the cardiac phenotype in neonatal cardiomyocytes [@B30].

Most of the four up-regulated and two down-regulated lncRNAs have no official Human Genome Nomenclature Committee symbol and their function is still unclear. However, some studies have been shown that Ywhae play a critical role in many diseases, such as HIV neurocognitive impairment [@B31], neuronal migrational defects [@B32], bipolar disorder [@B33] and endometrial stromal sarcoma [@B34].

Although we have identified some differentially expressed lncRNAs during the cardiac differentiation, it is too early for us to confirm their relationship with cardiac malformation. Therefore, subgroup analysis of lncRNAs should be performed to explore this relationship in the future. In addition, most lncRNAs have a distinct spatial and temporal specificity in the process of organismal differentiation and development. It has been shown that lncRNAs have different expression patterns in different parts of the brain [@B35]. We should sample more cells from different times in the process of differentiation, such as d4, d6 and d8, to examine alterations in lncRNA expression in the early stage of differentiation.

Materials and methods
=====================

P19 cell culture and induction of differentiation
-------------------------------------------------

P19 cells were bought from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured in complete medium (α-MEM + 10% fetal bovine serum, FBS + 100 U/ml penicillin + 100ug/ml streptomycin, pH 7.2-7.4) (α-MEM, FBS, penicillin and streptomycin, Gibco-BRL, Grand Island, NY, USA) in a 5% CO~2~atmosphere at 37°C. During differentiation, P19 cells were maintained in suspension as aggregates for 4 days in complete medium containing 1% dimethylsulfoxide (DMSO, Sigma, St. Louis, MO, USA) in bacteriological dishes. On day 4, the cell aggregates were transferred to cell culture flasks and then adherently cultivated from the 5^th^ to the 10^th^ day without DMSO. The culture medium was replaced every 2 days. We harvested cells on differentiation day 0 and day 10. The morphological changes in P19 cells were observed under an inverted microscope (Nikon Eclipse TE300, Tokyo, Japan) equipped with phase-contrast objectives and a digital camera (Nikon E4500).

Quantitative real time-PCR (qPCR) and western blotting
------------------------------------------------------

Total RNA was extracted from the harvested cells using a mirVana extraction kit (Ambion, Austin, TX, USA), following the manufacturer\'s protocol. RNA was measured using a NanoDrop spectrophotometer (NanoDrop, Wilmington, DE, USA) to assess its quantity and quality, and stored at -80°C. In general, we simultaneously performed RNA extraction and cDNA transcription for all subjects. The total RNA was reverse-transcribed to cDNA with a High-Capacity cDNA reverse transcription kit (Applied Biosystems, Austin, USA.). According to the manufacturer\'s protocol, we used 1µg of mRNA to activate 20µl of the reverse transcription reaction. The reaction comprised 25°C for 10min, 37°C for 120min, 85°C for 5 min and a hold at 4°C. Subsequently, real-time PCR was performed in triplicate for each sample and included no-template negative controls. For the final volume of 20 µl reaction, 1 µl of synthesized cDNA was mixed with 8 µl of diethylpyrocarbonate (DEPC)-treated water, 10 µl of TaqMan Gene Expression Master Mix and 1 µl of cardiac troponin T (cTnT) / β-actin TaqMan Gene Expression Assay (Applied Biosystems, cTnT ID: Mm01290256_m, β-actin ID: Mm00607939_s1). The reaction conditions comprised 50°C for 2min, 95°C for 10min; followed by 40 cycles of 95°C for 15s and 60°C for 1min on the ABI 7500 Real-Time PCR system (Applied Biosystems). β-actin was used as a reference to obtain the relative expression of cTnT, which was determined with the comparative cycle threshold (CT) (2^-△CT^) method, in which △CT = C~T\ cTnT~-C~T\ β-actin~.

A monoclonal rabbit anti-cTnT antibody and a monoclonal rabbit anti-β-actin antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Cells were broken using the lysis buffer provided in the total protein extraction kits (KeyGen, Inc., China). The lysate supernatant was obtained after centrifugation at 14000×g for 30min at 4°C. We then measured the protein concentration with a BCA protein detection kit (KeyGen, Inc., China). Western blotting was conducted as previously described [@B16].

Construction of the lncRNA microarray
-------------------------------------

We pooled three replicate samples of cells on day 0 and day 10 of DMSO exposure, respectively, to perform lncRNA microarray analysis. Total RNA was isolated from the two samples as above and was quantified using a NanoDrop spectrophotometer (NanoDrop). RNA integrity was assessed by standard denaturing agarose gel electrophoresis. Each sample was then amplified and transcribed into fluorescent cRNA along the entire length of the transcripts without 3\' bias, using a random priming method. The labeled cRNAs were hybridized onto the Mouse LncRNA Array v2.0 (8 x 60K, Arraystar). The hybridized arrays were washed, fixed and scanned with using the Agilent DNA Microarray Scanner (part number G2505C). Data were extracted using Agilent Feature Extraction software (version 11.0.1.1). Quantile normalization and subsequent data processing were performed using the GeneSpring GX v11.5.1 software package (Agilent Technologies). Differentially expressed LncRNAs between the two samples were identified by Fold Change filtering. The threshold set for upregulated lncRNAs was more than five-fold and for downregulated lncRNAs it was more than three-fold. The lncRNAs discussed in this article were carefully collected from the most authoritative databases, such as RefSeq, UCSC Knowngenes, Ensembl and many related literature.

Validation of differentially expressed lncRNAs
----------------------------------------------

Total RNA extraction and cDNA transcription were conducted as above. For real-time PCR, we added 1µl of cDNA to 12.5µl of SYBR-Green Gene Expression Master Mix (Applied Biosystems, Inc), 10.5µl f DEPC-treated water and 0.5µl of reverse and forward primers. cDNA was amplified for 50 cycles on the ABI 7500 Real-Time PCR system (Applied Biosystems). The primers sequences used are listed in Table [3](#T3){ref-type="table"}. GAPDH was used as a reference to obtain the relative expression of target lncRNAs which was determined with the comparative cycle threshold (CT) (2^-△CT^) method, in which △CT = C~T\ target\ lncRNA~- C~T\ GAPDH~.

Statistical analysis
--------------------

All statistical analyses were performed using the Student\'s t-test with SPSS software version 13.0 (SPSS, Inc, Chicago, IL, USA). P-values less than 0.05 were considered statistically significant, and all the statistical tests were two-sided.

Conclusion
==========

In conclusion, we identified a set of lncRNAs that were aberrantly expressed in cardiomyocytes compared to undifferentiated P19 cells, which will provide the foundation for the further study of the biological function of lncRNAs and the mechanism of heart development.
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![Morphology of P19 cells during differentiation into cardiac myocytes (day 0, day 4, day 8, day 10). P19 cells were aggregated for 4 days and colonies of beating cells were observed on day 10 under an inverted microscope, as described in Materials and methods.](ijmsv11p0500g001){#F1}

![Relative expression of cTnT at day 10 compared with day 0. The experiment was repeated three times with consistent results. \*\*\*p\<0.001](ijmsv11p0500g002){#F2}

![Expression of the cTnI protein in P19 cells. Total proteins were isolated from P19 cells and analyzed by western blotting. Lane 1, day 0; Lane 2, day 10. The experiment was repeated three times with consistent results.](ijmsv11p0500g003){#F3}

![Validation of lncRNA microarray data using real-time RT-PCR. The real-time RT-PCR reactions were repeated three times for every lncRNA. \* p \< 0.05, \*\*p\<0.01, \*\*\*p\<0.001.](ijmsv11p0500g004){#F4}

![The 8 differentiated expressed lncRNAs at different time points of the differentiation. (Because the relative expression of uc007keu was much higher than the other lncRNAs, we performed two histograms for clarity and aesthetic feeling.)](ijmsv11p0500g005){#F5}

###### 

40 differentially expressed lncRNAs.

  Regulation                  lncRNA       chromosomal localization   RNA length   Start locus   Stop locus
  --------------------------- ------------ -------------------------- ------------ ------------- ------------
  28 up-regulated lncRNAs     AK158639     chr2                       417          169458512     169458928
  uc007vie.1                  chr15        4168                       12959401     12963569      
  ENSMUST00000159006          chr6         253                        52108522     52112019      
  AK166199                    chr13        1351                       16122089     16123440      
  AK052877                    chr19        1301                       30638978     30640279      
  uc009biz.1                  chr6         606                        36664928     36665534      
  uc009pal.1                  chr9         3270                       41388823     41400910      
  uc009eqi.1                  chr6         2534                       143777066    143779600     
  ENSMUST00000101005          chr6         1302                       119912384    119913686     
  ENSMUST00000124503          chr11        454                        35163570     35164287      
  AK020106                    chr11        802                        69615637     69616437      
  AK142834                    chrX         2388                       118021841    118024227     
  uc007cpz.1                  chr1         2470                       135197537    135200007     
  uc007prv.1                  chr13        2198                       21925626     21929399      
  uc009byc.1                  chr6         545                        52122879     52124051      
  AK078053                    chr18        1378                       36459754     36461132      
  NR_024257                   chr2         4066                       9802872      9808394       
  AK089560                    chr5         2683                       13525726     13528408      
  AK142308                    chr18        1262                       37965377     37966636      
  AK046177                    chr13        606                        117639650    117640255     
  AK135062                    chr7         2464                       104057136    104059598     
  AK138321                    chr11        2303                       47744849     47747149      
  uc008sdp.1                  chr4         3039                       22409926     22412965      
  uc008fug.1                  chr18        948                        83172461     83173409      
  AK028129                    chr3         2428                       96043315     96045742      
  uc008xbx.1                  chr5         802                        34516538     34517340      
  uc008euf.1                  chr18        1629                       43480650     43482279      
  ENSMUST00000127359          chr14        344                        47007193     47008957      
  12 down-regulated lncRNAs   uc007keu.1   chr11                      1635         75565382      75579340
  AK033485                    chr1         2241                       54532201     54534442      
  uc007pyj.1                  chr13        1179                       28700386     28977221      
  uc008sac.1                  chr4         1060                       11893711     11921427      
  AK137254                    chr7         5124                       127773275    127778400     
  AK028257                    chr14        272                        55735163     55735434      
  BC030048                    chr17        1092                       35087185     35088238      
  BC030682                    chr7         1343                       71031236     71032537      
  ENSMUST00000117553          chr2         1125                       111840336    111841461     
  ENSMUST00000172121          chr6         291                        64941211     64941502      
  AK010244                    chr2         1771                       125082798    125084785     
  uc008mcn.1                  chr2         1771                       125082798    125084785     

###### 

lncRNAs differentially expressed between cardiomyocytes that differentiated from P19 cells (day 10) compared with normal cells (day 0).

  up-regulated lncRNA   fold change   GeneSymbol   down-regulated lncRNA   fold change   GeneSymbol
  --------------------- ------------- ------------ ----------------------- ------------- ------------
  ENSMUST00000159006    46.21         Gm15051      uc007keu.1              8.07          Ywhae
  uc009byc.1            21.50         AK142386     AK028257                4.71          
  AK089560              15.47                      BC030682                3.4           
  ENSMUST00000101005    6.29          Wnk1                                               
  ENSMUST00000124503    5.11          Gm12122                                            

###### 

Primers for real-time RT-PCR.

  Gene name                   Primers                     Tm (℃)
  --------------------------- --------------------------- --------
  ENSMUST00000159006          P5:GGAGCTGACTTGGAGCACTG     60
  P3:AACAGACCTCTTGCCAGTTCA                                
  uc009byc.1                  P5:AACTTGCGTCTGGAGTTGGG     60
  P3:CCCAGAATAGCAGCACCTCA                                 
  AK089560                    P5:ATGCTTTCCCAGGGTGTGTT     60
  P3:GGCTAGGATTTCCCGACGAG                                 
  ENSMUST00000101005          P5:TGTTGATACAGCCTCAGTCCAT   60
  P3:GTTGGAAGTGGCGAGTTTGG                                 
  ENSMUST00000124503          P5:GACACGAAGAAGAACCACATCA   60
  P3:GCCTGCGAGGATTCTATTTATT                               
  uc007keu.1                  P5:AAAATGTGATTGGAGCCAGAAG   60
  P3:GTCCTCTCCTCCCTTGTTTTCT                               
  AK028257                    P5:CTCTCCTCTCCGCTTCTCTCT    60
  P3:CATCCCAGCACAAATCAATGT                                
  BC030682                    P5:GACCTGGCTCTTCCTCAT       60
  P3:TTCCATCTGTCCGTTCTG                                   
  GAPDH                       P5:ATTCAACGGCACAGTCAA       60
  P3:CTCGCTCCTGGAAGATGG                                   
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